Abstract
In this data article, we provide subgroup specific baseline characteristics and serum sphingosine-1-phosphate (S1P) concentrations for healthy individuals within the Study of Health in Pomerania (SHIP)-TREND cohort. After exclusion of subjects with cardiovascular disease, diabetes mellitus, hypertension, metabolic syndrome, elevated liver enzymes and/or chronic kidney disease stadium III or IV, four subgroups were defined according to different limits for body mass index (BMI), alterations in blood lipid levels and smoking status. Tables show respective clinical and laboratory parameters stratified by gender. Serum S1P concentrations are also stratified by age groups. The data presented herein is related to the research article entitled “Reference intervals for serum sphingosine-1-phosphate in the population-based Study of Health in Pomerania” (E. Moritz, D. Wegner, S. Groß, M. Bahls, M. Dörr, S.B. Felix, T. Ittermann, S. Oswald, M. Nauck, N. Friedrich, R.H. Böger, G. Daum, E. Schwedhelm, B.H. Rauch, Clin Chim Acta. 468 (2017) 25–31) [1].
Keywords: Clinical and laboratory data, Sphingosine-1-phosphate, Study of Health in Pomerania, Subgroup formation
Specifications Table
| Subject area | Medicine |
| More specific subject area | Clinical chemistry, Biomarker development, Sphingosine-1-phosphate |
| Type of data | Tables |
| How data was acquired | Blood pressure: HEM-705CP (Omron, Tokyo, Japan) |
| HbA1c: Diamat Analyzer (Bio-Rad, Munich, Germany) | |
| Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides and creatinine: Dimension Vista 500 analytical system (Siemens AG, Erlangen, Germany) | |
| Sphingosine-1-phosphate: liquid chromatography-tandem mass spectrometry; Varian L1200 MS/MS (Agilent Technologies, Waldbronn, Germany) | |
| Data format | Analyzed |
| Experimental factors | Blood samples were drawn from the cubital vein of 4.420 participants of the Study of Health in Pomerania (SHIP)-TREND cohort. Aliquots were analyzed immediately or stored at −80 °C. |
| Experimental features | After the definition of different subgroups within the SHIP-TREND cohort, the subgroups were characterized by clinical as well as laboratory parameters and sphingosine-1-phosphate concentrations. |
| Data source location | Greifswald, Germany |
| Data accessibility | Data is with this article. |
Value of the data
-
•
The data presented in this DIB article provides further insight into subgroup formation and S1P concentrations depending on BMI limit, altered blood lipid levels and smoking status.
-
•
The data will facilitate the determination of S1P reference intervals in future population-based cohorts.
-
•
The data can be used for establishing S1P as cardiovascular biomarker.
1. Data
In this Data in Brief article, we provide clinical as well as laboratory baseline characteristics and serum sphingosine-1-phosphate (S1P) concentrations that extend the results reported in [1] for four different subgroups of healthy individuals within the Study of Health in Pomerania (SHIP)-TREND cohort. In any case, subjects with cardiovascular disease, diabetes mellitus, hypertension, metabolic syndrome, elevated liver enzymes and/or chronic kidney disease stadium III or IV were excluded. With respect to body mass index (BMI), the exclusion limit for the first subgroup was 25 kg/m2 (‘BMI<=25’, n=805; Table 1) and 35 kg/m2 for the second subgroup (‘BMI<=35’, n=1474; Table 2), respectively. For the third subgroup altered blood lipid levels were an additional exclusion criterion (‘Normolipidemia’, n=740; Table 3) and smoking for the fourth subgroup (‘Non-Smokers’, n=884; Table 4), respectively. Here, in each case the BMI limit was defined as 30 kg/m2. All parameters were stratified by gender, median serum S1P concentrations also by age groups.
Table 1.
Baseline characteristics and serum S1P concentrations of the subgroup ‘BMI<=25’.
| Women | Men | p-Value | |
|---|---|---|---|
| n | 579 | 226 | |
| Age, years | 39 (31, 48) | 37 (27, 46) | 0.001 |
| Body mass index, kg/m² | 22 (21, 24) | 23 (22, 24) | <0.001 |
| Systolic blood pressure, mmHg | 109 (102, 118) | 121 (114, 129) | <0.001 |
| Diastolic blood pressure, mmHg | 70 (65, 75) | 73 (68, 79) | <0.001 |
| HbA1c, % | 4.9 (4.6, 5.3) | 5.1 (4.8, 5.4) | <0.001 |
| Total cholesterol, mmol/L | 5.10 (4.50, 5.90) | 4.75 (4.20, 5.70) | 0.001 |
| HDL cholesterol, mmol/L | 1.71 (1.47, 1.92) | 1.34 (1.14, 1.56) | <0.001 |
| LDL cholesterol, mmol/L | 2.94 (2.40, 3.56) | 2.92 (2.43, 3.62) | 0.512 |
| Triglycerides, mmol/L | 0.93 (0.70, 1.25) | 1.05 (0.73, 1.43) | 0.007 |
| Serum creatinine, µmol/L | 66 (59, 73) | 80 (73, 89) | <0.001 |
| eGFR, mL/min/1.73 m² | 99 (88, 111) | 104 (94, 113) | <0.001 |
| Sphingosine-1-phosphate, µM | 0.802 (0.687, 0.908) | 0.788 (0.688, 0.900) | 0.874 |
| 20–29 years | 0.820 (0.689, 0.921) | 0.796 (0.704, 0.912) | |
| 30–39 years | 0.806 (0.696, 0.898) | 0.796 (0.687, 0.906) | |
| 40–49 years | 0.786 (0.679, 0.903) | 0.754 (0.669, 0.881) | |
| 50–59 years | 0.811 (0.712, 0.895) | 0.773 (0.675, 0.892) | |
| >=60 years | 0.735 (0.653, 0.973) | 0.871 (0.716, 0.997) |
Continuous data are given as median (25th, 75th percentile), Mann-Whitney U-test was used for comparison between women and men. eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 2.
Baseline characteristics and serum S1P concentrations of the subgroup ‘BMI<=35’.
| Women | Men | p-Value | |
|---|---|---|---|
| n | 969 | 505 | |
| Age, years | 41 (33, 51) | 40 (30, 51) | 0.058 |
| Body mass index, kg/m² | 24 (22, 27) | 25 (23, 27) | <0.001 |
| Systolic blood pressure, mmHg | 111 (104, 119) | 124 (116, 130) | <0.001 |
| Diastolic blood pressure, mmHg | 71 (67, 76) | 75 (70, 80) | <0.001 |
| HbA1c, % | 5.0 (4.7, 5.3) | 5.1 (4.8, 5.4) | <0.001 |
| Total cholesterol, mmol/L | 5.20 (4.60, 6.00) | 5.10 (4.40, 5.80) | 0.003 |
| HDL cholesterol, mmol/L | 1.66 (1.44, 1.89) | 1.30 (1.13, 1.52) | <0.001 |
| LDL cholesterol, mmol/L | 3.09 (2.48, 3.68) | 3.22 (2.60, 3.83) | 0.010 |
| Triglycerides, mmol/L | 0.98 (0.74, 1.32) | 1.16 (0.82, 1.60) | <0.001 |
| Serum creatinine, µmol/L | 67 (59, 73) | 83 (75, 91) | <0.001 |
| eGFR, mL/min/1.73 m² | 98 (86, 110) | 99 (89, 111) | 0.014 |
| Sphingosine-1-phosphate, µM | 0.808 (0.694, 0.920) | 0.797 (0.701, 0.922) | 0.653 |
| 20–29 years | 0.820 (0.690, 0.931) | 0.781 (0.703, 0.919) | |
| 30–39 years | 0.807 (0.689, 0.912) | 0.813 (0.697, 0.939) | |
| 40–49 years | 0.806 (0.694, 0.925) | 0.782 (0.703, 0.910) | |
| 50–59 years | 0.805 (0.705, 0.904) | 0.807 (0.702, 0.942) | |
| 60–69 years | 0.851 (0.694, 0.999) | 0.818 (0.718, 0.928) | |
| >=70 years | 0.762 (0.674, 0.913) | 0.721 (0.619, 0.872) |
Continuous data are given as median (25th, 75th percentile), Mann–Whitney U-test was used for comparison between women and men. eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 3.
Baseline characteristics and serum S1P concentrations of the subgroup ‘Normolipidemia’.
| Women | Men | p-Value | |
|---|---|---|---|
| n | 524 | 216 | |
| Age, years | 38 (31, 45) | 34 (27, 46) | 0.033 |
| Body mass index, kg/m² | 23 (21, 26) | 25 (22, 26) | <0.001 |
| Systolic blood pressure, mmHg | 110 (103, 118) | 123 (115, 130) | <0.001 |
| Diastolic blood pressure, mmHg | 70 (66, 75) | 73 (68, 79) | <0.001 |
| HbA1c, % | 4.9 (4.6, 5.2) | 5.0 (4.8, 5.3) | <0.001 |
| Total cholesterol, mmol/L | 4.70 (4.20, 5.20) | 4.40 (4.10, 4.90) | <0.001 |
| HDL cholesterol, mmol/L | 1.67 (1.46, 1.90) | 1.39 (1.18, 1.56) | <0.001 |
| LDL cholesterol, mmol/L | 2.65 (2.23, 2.97) | 2.63 (2.26, 3.02) | 0.221 |
| Triglycerides, mmol/L | 0.89 (0.66, 1.16) | 0.90 (0.64, 1.23) | 0.639 |
| Serum creatinine, µmol/L | 67 (59, 73) | 83 (75, 91) | <0.001 |
| eGFR, mL/min/1.73 m² | 99 (88, 112) | 102 (92, 113) | 0.114 |
| Sphingosine-1-phosphate, µM | 0.805 (0.686, 0.918) | 0.788 (0.682, 0.920) | 0.531 |
| 20–29 years | 0.812 (0.678, 0.935) | 0.785 (0.705, 0.881) | |
| 30–39 years | 0.801 (0.685, 0.902) | 0.838 (0.680, 0.954) | |
| 40–49 years | 0.807 (0.691, 0.920) | 0.754 (0.673, 0.883) | |
| 50–59 years | 0.814 (0.701, 0.885) | 0.827 (0.703, 0.973) | |
| 60–69 years | 0.870 (0.644, 1.069) | 0.797 (0.652, 0.893) | |
| >=70 years | 0.745 (0.692, 0.768) | 0.612 (0.503, 0.810) |
Continuous data are given as median (25th, 75th percentile), Mann–Whitney U-test was used for comparison between women and men. eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 4.
Baseline characteristics and serum S1P concentrations of the subgroup ‘Non-Smokers’.
| Women | Men | p-Value | |
|---|---|---|---|
| n | 590 | 294 | |
| Age, years | 42 (34, 53) | 41 (32, 51) | 0.064 |
| Body mass index, kg/m² | 24 (22, 26) | 25 (23, 27) | <0.001 |
| Systolic blood pressure, mmHg | 111 (104, 120) | 124 (116, 130) | <0.001 |
| Diastolic blood pressure, mmHg | 71 (66, 76) | 74 (70, 79) | <0.001 |
| HbA1c, % | 5.0 (4.6, 5.3) | 5.1 (4.8, 5.4) | <0.001 |
| Total cholesterol, mmol/L | 5.30 (4.60, 6.10) | 5.10 (4.40, 5.80) | 0.001 |
| HDL cholesterol, mmol/L | 1.71 (1.48, 1.97) | 1.33 (1.17, 1.52) | <0.001 |
| LDL cholesterol, mmol/L | 3.08 (2.47, 3.70) | 3.18 (2.61, 3.82) | 0.091 |
| Triglycerides, mmol/L | 0.94 (0.70, 1.29) | 1.09 (0.79, 1.52) | <0.001 |
| Serum creatinine, µmol/L | 67 (59, 74) | 84 (76, 91) | <0.001 |
| eGFR, mL/min/1.73 m² | 97 (85, 108) | 98 (88, 109) | 0.096 |
| Sphingosine-1-phosphate, µM | 0.802 (0.685, 0.910) | 0.782 (0.698, 0.908) | 0.934 |
| 20–29 years | 0.828 (0.696, 0.933) | 0.771 (0.684, 0.860) | |
| 30–39 years | 0.801 (0.682, 0.901) | 0.854 (0.703, 0.969) | |
| 40–49 years | 0.783 (0.683, 0.896) | 0.776 (0.700, 0.904) | |
| 50–59 years | 0.808 (0.699, 0.896) | 0.795 (0.705, 0.871) | |
| 60–69 years | 0.813 (0.668, 1.010) | 0.806 (0.684, 0.903) | |
| >=70 years | 0.766 (0.673, 0.916) | 0.705 (0.583, 0.944) |
Continuous data are given as median (25th, 75th percentile), Mann–Whitney U-test was used for comparison between women and men. eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
2. Experimental design, materials and methods
2.1. Study population
The population-based SHIP-TREND cohort comprises 4420 inhabitants of West Pomerania. A detailed description of the cohort study can be found in Völzke et al. [2], [3]. The study conformed to the principles of the Declaration of Helsinki and was approved by the Ethics Committee of the University of Greifswald. All participants provided informed written consent. The exclusion criteria for subgroup formation have been precisely defined in [1].
2.2. Clinical and laboratory parameters
Clinical data acquisition and analytical procedures, i.e. for determining laboratory data and S1P concentrations, have been reported previously [1].
2.3. Data analysis
Continuous data are given as median (25th and 75th percentiles). The non-parametric Mann–Whitney U-test was used for comparison between women and men.
Acknowledgments
We gratefully thank Anna Steenpaß and Mariola Kastner for their excellent technical assistance. The contributions to data collection made by field workers, study physicians, ultrasound technicians, interviewers, and computer assistants are gratefully acknowledged. This work was funded in part by a grant from the DZHK (Deutsches Zentrum für Herz-Kreislauf-Forschung e.V. Grant 81X2400111). The SHIP-TREND study is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (Grants 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania.
References
- 1.E. Moritz, D. Wegner, S. Groß, M. Bahls, M. Dörr, S. Felix, T. Ittermann, S. Oswald, M. Nauck, N. Friedrich, R. Böger, G. Daum, E. Schwedhelm, B. Rauch Reference intervals for serum sphingosine-1-phosphate in the population-based study of health in Pomerania. Clin Chim Acta. 468 (2017) 25–31. [DOI] [PubMed]
- 2.Völzke H., Ittermann T., Schmidt C.O. Prevalence trends in lifestyle-related risk factors: two cross-sectional analyses with a total of 8728 participants from the study of health in Pomerania from 1997 to 2001 and 2008 to 2012. Dtsch. A¨rztebl. Int. 2015;112(11):185–192. doi: 10.3238/arztebl.2015.0185. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Völzke H., Alte D., Schmidt C.O., Radke D., Lorbeer R., Friedrich N. Cohort profile: the study of health in Pomerania. Int. J. Epidemiol. 2011;40(2):294–307. doi: 10.1093/ije/dyp394. [DOI] [PubMed] [Google Scholar]